Tvardi Therapeutics, Inc.
TVRD
NASDAQ·Healthcare·Biotechnology·Mkt cap $17.9M
$1.91
▲ +3.24%
P/E
—
Mkt Cap
$17.9M
52-Wk Range
$1.50–$43.65
52-Week Range
$1.50 - $43.65
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 93.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Novel oral STAT3 inhibitor with differentiated mechanism of action targeting fibrosis pathways
- First-mover advantage in STAT3-targeted fibrosis treatment with clinical validation in Phase 2 trials
- Broad applicability across multiple fibrosis-driven indications with significant unmet medical needs
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
Advancement of TTI-101 through Phase 2 clinical trials with potential for accelerated regulatory pathways
Value
Valuation data unavailable
Momentum
Falling
-33.0% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying TVRD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$0.69 vs -$0.70 consensus (+2.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+2.0%
Revenue trend · last 8Q
—
-52%
+20%
—
-100%
-100%
-100%
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.6M
$1.5M
$2.6M
$0
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
0%
Sell
20%
Median Price Target
—
Latest: Piper Sandler · Jul 8, 2026
vs Industry
How TVRD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related